a portrait photograph of a woman with bobbed curly hair wearing a white blouse

Dr Rebecca Harding

Entrepreneurs want to change things all the time. So says Dr Rebecca Harding, economist and serial entrepreneur. Rebecca’s career has certainly involved breaking traditions and rattling cages. “I’ve always been a self starter who knows my own mind and has a clear sense of direction in my education and career,” she says.

When her comprehensive school did not offer A’ level German she joined lessons at the local boys’ grammar. Participating in drama clubs and student productions has also helped her throughout her professional life, she says. At Sussex University Rebecca gained a BA in Economics with German. The interdisciplinary nature of the course has proved very helpful in business life, she says. “It enabled me to study politics, philosophy, economics, sociology and international relations.”

 After taking a doctorate in Technology and HR, she began working in academe, which she describes as “a brilliant training for entrepreneurship because academics spend their time generating ideas and thinking of ways to solve problems.” At London Business School, Rebecca ran the Global Entrepreneurship Monitor — a survey of entrepreneurship worldwide. It helped her understand the power of data in helping people and driving success.

 In 2007, Rebecca founded her first company, Delta Economics, and began analysing why people start businesses and the challenges they face achieving growth. Her research showed that their motivation “is more about solving problems and innovating than making money.” It led to her second start-up, Coriolis Technologies, formed in 2017 to provide trade and trade finance data and analytics for the trade finance sector.

“Global trade is worth $21 trillion a year and the value of trade finance is between $15tn and $17tn: 90 per cent of it is still paper-based,” she says. “Digitising global trade is a huge opportunity.”

Dr Juliet Webster

Uninspired by her teachers, Dr Juliet Webster left school to take a secretarial course. She also signed up for A’level sociology — a subject not then on the school curriculum.

It was the beginning of a lengthy and prolific academic career studying the gender dynamics of job automation, digital labour, and how employment has evolved since technology began to appear in the workplace.

“What drew me in was the sociology of industrial relations and the Marxist theory of capital,” she says. “I was really interested in the lessons for the twentieth century from the early introduction of machinery.”

Topics she has examined in her many academic papers include virtual work, the gig economy, equal pay, people skills and social sustainability. She is particularly interested in how technology has impacted women’s lives.

Juliet’s career has also spanned practical action in NGOs, and policy making, including for the European Commission Directorate General for Employment. She currently has her own consultancy in London,Work & Equality Research, and is Adviser for the Gender and ICT Programme, IN3, at the Open University of Catalonia.

Juliet does not discourage young women from careers in technologies such as computer science. But she is concerned about the current trend towards flexible working, which includes an increase in short-term contracts, content farming and offshoring. “These practices blur the boundaries between work and home life, and can erode pay and conditions,” she says.

Paul Mason

Paul Mason is Director of Innovation Policy at Innovate UK, the UK’s innovation agency. The role gives him a key role in determining the future of technology across the nation.

It could have been different. An enthusiastic jazz player in his teens, he almost became a professional musician. But decided instead to study chemistry. The income prospects for a scientist were more reliable than for a freelance jazz player, he says. “Career choice has to be a compromise between what you love, what you do well and what people are prepared to pay for.”

Paul acknowledges the huge educational opportunities he has experienced, first at his local comprehensive then at Balliol College, Oxford. “The quality of staff at school and university, and the time they invested in their students’ education, was huge,” he says.

Graduating in 1984, he rejected merchant banking and took up a full-time job at Courtaulds, which had sponsored his degree. It was there that he first used a networked computer, which the company had installed for its researchers to share their work and exchange reports.

During 25 years in the chemical industry, Paul worked on a wide range of technologies and markets. At Courtaulds, he worked on industrial and apparel fibres, high-tech and packaging films, separation technologies, polymers for a range of applications including LCD polarising filters and sunglasses frames, dyeing technologies, anti-fouling coatings for shipping, and in many other areas including spells in Europe, the US and Japan. He went on to hold change management, manufacturing, and commercial roles in Akzo Nobel and CVC/Acordis.

In 2007, Paul became Head of Development at the newly-formed Technology Strategy Board, which later morphed into Innovate UK. He is responsible for corporate strategy and the programmes that support its development and implementation.

Over the years, Paul has set up and launched national innovation programmes in areas such as agriculture and food, stratified medicine, disease diagnosis and creative industries. In many of these, the UK is world-leading, he says.

Not every idea that gains funding can be expected to succeed. “We’ve invested in some individual projects that went nowhere, but that would happen in industry and with venture capital too – but the programmes overall have been successful.” In innovation the UK is punching well above its weight in many areas, he says, including in offshore renewable energy, creative and digital industries, automotive, aerospace, advanced manufacturing and service industries, and in pharmaceutical and medical industries. For instance, in advanced therapies “about 38% of all European clinical trials are being conducted in the UK.”